Skip to content
Peptidepedia

Semaglutide Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Dosage Protocols

Semaglutide dosing follows a mandatory titration schedule designed to minimize gastrointestinal side effects and improve tolerability. Initiating at full therapeutic doses significantly increases the rate of side effects. At any stage of the dose titration, the time can be extended if needed. For example, if side effects persist by week 4, a person can remain on 0.25 mg weekly for as many weeks as needed. In addition to pausing, dosage increases can be stopped at any level at which the desired weight loss is achieved.

Weight Management (Wegovy Protocol):

  • Weeks 1–4: 0.25 mg once weekly
  • Weeks 5–8: 0.5 mg once weekly
  • Weeks 9–12: 1.0 mg once weekly
  • Weeks 13–16: 1.7 mg once weekly
  • Week 17 onward: 2.4 mg once weekly (maintenance)

Glycemic Control (Ozempic Protocol):

  • Weeks 1–4: 0.25 mg once weekly
  • Weeks 5–8: 0.5 mg once weekly
  • Week 9 onward: 1.0 mg once weekly (may increase to 2.0 mg if needed)

Unlike anabolic compounds, semaglutide does not require cycling. Clinical evidence supports continuous long-term use, but some amount of weight may be regained after stopping the drug.

The STEP 1 trial extension (Wilding et al., 2022) demonstrated that participants who discontinued semaglutide regained approximately two-thirds of the weight they had lost within one year.

For those using research-grade semaglutide, precise dosing requires accurate reconstitution calculations and insulin syringes capable of measuring small volumes.

Frequently Asked Questions

This is strongly discouraged. Rapid dose escalation dramatically increases nausea, vomiting, and treatment discontinuation rates. The titration schedule exists specifically to improve tolerability.

Eat smaller, more frequent meals; avoid fatty or greasy foods; stay hydrated; eat slowly; and avoid lying down immediately after eating. Nausea typically improves after 4–8 weeks at each dose level.

Both contain semaglutide. Ozempic is approved for diabetes (maximum 2.0 mg), while Wegovy is approved for weight management (maximum 2.4 mg) with a different titration schedule. The molecule is identical.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. FDA Approval Announcement for Wegovy (2021).
  2. Semaglutide Mechanism of Action Review. PMC.
  3. Central Nervous System Effects of GLP-1 Agonists. Nature Medicine.
  4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
  5. Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity (STEP 4). JAMA. 2021.
  6. Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. 2021.
  7. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. 2023.
  8. Wegovy Prescribing Information. FDA.
  9. FDA Statement on Compounded Semaglutide.
←Read the full Semaglutide guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”